Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study.
van der Kleij MBA, Guchelaar NAD, Meertens M, Westerdijk K, Giraud EL, Bleckman RF, Groenland SL, van Eerden RAG, Imholz ALT, Vulink AJE, Otten HM, Fiebrich-Westra HB, Lubberman FJE, Desar IME, Moes DAR, Touw DJ, Koolen SLW, Gelderblom H, Reyners AKL, van Erp NP, Mathijssen RHJ, Huitema ADR; Dutch Pharmacology Oncology Group (DPOG); Steeghs N. van der Kleij MBA, et al. Br J Cancer. 2024 Sep;131(5):843-851. doi: 10.1038/s41416-024-02789-2. Epub 2024 Jul 6. Br J Cancer. 2024. PMID: 38971952 Free PMC article.
Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.
Woei-A-Jin FJSH, Van Nieuwenhuyse T, van Erp NP, Beuselinck B, Stroobants S, Moes DJAR, Osanto S, Spriet I. Woei-A-Jin FJSH, et al. Among authors: moes djar. J Clin Oncol. 2018 Oct 20;36(30):3062-3064. doi: 10.1200/JCO.2018.79.3182. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188790 No abstract available.
The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).
Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP. Lubberman FJE, et al. Among authors: moes djar. Clin Pharmacol Ther. 2019 Nov;106(5):1076-1082. doi: 10.1002/cpt.1515. Epub 2019 Jul 9. Clin Pharmacol Ther. 2019. PMID: 31125423 Clinical Trial.
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective Study.
Groenland SL, van Eerden RAG, Verheijen RB, Koolen SLW, Moes DJAR, Desar IME, Reyners AKL, Gelderblom HJ, van Erp NP, Mathijssen RHJ, Huitema ADR, Steeghs N. Groenland SL, et al. Among authors: moes djar. Ther Drug Monit. 2019 Oct;41(5):561-567. doi: 10.1097/FTD.0000000000000654. Ther Drug Monit. 2019. PMID: 31568233 Review.
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
Yin A, Ettaieb MHT, Swen JJ, van Deun L, Kerkhofs TMA, van der Straaten RJHM, Corssmit EPM, Gelderblom H, Kerstens MN, Feelders RA, Eekhoff M, Timmers HJLM, D'Avolio A, Cusato J, Guchelaar HJ, Haak HR, Moes DJAR. Yin A, et al. Among authors: moes djar. Clin Pharmacokinet. 2021 Jan;60(1):89-102. doi: 10.1007/s40262-020-00913-y. Clin Pharmacokinet. 2021. PMID: 32607875 Free PMC article.
109 results